Clinical Trials Browser

INDUSTRY × Has results × binimetinib × Clear all

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 1 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1/2 Terminated

34 enrolled 44 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Phase 1 Terminated

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT03374254 2024-11-21

KEYNOTE-651

Phase 1 Completed

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1 Completed

56 enrolled 158 charts

Melanoma

NCT05810740 2024-09-19

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1 Completed

37 enrolled 25 charts

Melanoma

NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Phase 1/2 Completed

189 enrolled 44 charts

Other solid neoplasm

Solid Tumors Harboring a BRAF V600 Mutation

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Phase 2 Completed

183 enrolled 35 charts

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT02928224 2023-12-21

BEACON CRC

Phase 3 Completed

702 enrolled 82 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT01849874 2023-10-30

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 3 Terminated

341 enrolled 15 charts

Low-grade Serous Ovarian Cancer

NCT03911869 2023-05-31

POLARIS

Phase 2 Terminated

13 enrolled 55 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03271047 2022-01-04

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Phase 2 Completed

75 enrolled 17 charts

Neoplasms

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3 Completed

402 enrolled 21 charts

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

NCT01885195 2021-02-21

SIGNATURE

Phase 2 Completed

110 enrolled 18 charts

Other hematologic neoplasmThoracic

Noonan Syndrome 5, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01801358 2020-09-16

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Phase 1/2 Terminated

38 enrolled 31 charts

Uveal Melanoma, Melanoma